Pet biotech Kindred Biosciences sets terms for $40 million IPO

Comment

Shutterstock photo

Kindred Biosciences, a clinical-stage biotech developing pet therapeutics, announced terms for its IPO on Monday. The Burlingame, CA-based company plans to raise $40 million by offering 5.8 million shares at a price range of $6 to $8. At the midpoint of the proposed range, Kindred Biosciences would command a market value of $93 million.

Kindred Biosciences, which was founded in 2012, plans to list on the NASDAQ under the symbol KIN. Kindred Biosciences initially filed confidentially on October 2, 2013. BMO Capital Markets and Guggenheim Securities are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com